Relevant bibliographies by topics / Anaphylaxie

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Anaphylaxie'

Author: Grafiati
Published: 4 June 2021
Last updated: 28 September 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Anaphylaxie.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Anaphylaxie"

1

Happle, C. "Nahrungsmittelallergien und Anaphylaxie." Kinder- und Jugendmedizin 18, no. 04 (August 2018): 240–48. http://dx.doi.org/10.1055/s-0038-1669485.

Full text
Abstract:
ZusammenfassungNahrungsmittelallergien sind der häufigste Auslöser für Anaphylaxien im Kindesalter. Auch wenn es in den vergangenen Jahren neue Daten zur Ätiologie und interessante Ansätze zur spezifischen Immuntherapie von Nahrungsmittelallergien gab, gibt es bisher keine Heilung. Die Behandlung besteht primär in Allergenkarenz und symptomatischer Medikation. Dabei kommt der Notfalltherapie eine besondere Bedeutung zu. Das Risiko plötzlich auftretender schwerer Symptome mit potenziell fatalem Ausgang kann für betroffene Patienten und ihre Familien eine starke Einschränkung ihrer Lebensqualität bedeuten. Schulungen im Erkennen und Umgang von Anaphylaxien und in der Anwendung eines Adrenalin-Autoinjektors sind für gefährdete Patienten essenziell. Der vorliegende Artikel gibt nach einer kurzen Einführung zu Pathophysiologie, Epidemiologie und Behandlung von Nahrungsmittelallergien einen aktuellen Überblick zur Literatur und zu Handlungsempfehlungen bei Nahrungsmittel-assoziierter Anaphylaxie. Er soll als Entscheidungshilfe im Hinblick auf die Verordnung eines Adrenalin-Autoinjektors bei Nahrungsmittelallergie dienen und gibt Empfehlungen für das Notfalltraining von Kindern und Familien mit Anaphylaxierisiko.
APA, Harvard, Vancouver, ISO, and other styles
2

Prenzel, F., and U. Miehe. "Anaphylaxie." Kinder- und Jugendmedizin 12, no. 01 (2012): 26–30. http://dx.doi.org/10.1055/s-0038-1629173.

Full text
Abstract:
ZusammenfassungDer Ausdruck „Anaphylaxie“ beschreibt eine schwere, lebensbedrohliche generalisierte oder systemische Hypersensitivitätsreaktion. Symptome einer Anaphylaxie können inner-halb von Sekunden bis Minuten nach Allergenkontakt auftreten. Sie manifestieren sich an Haut, Atemwegen, kardiovaskulärem System, Gastrointestinaltrakt und ZNS. Im Kindes- und Jugendalter sind Nahrungsmittel gefolgt von Insektenstichen und Medikamenten die häufigsten Auslöser einer anaphylaktischen Reaktion. Eine schnelle Diagnosefin-dung sowie die frühe Therapieeinleitung sind der Schlüssel für ein erfolgreiches Management der Anaphylaxie. Bei der Akuttherapie der Anaphylaxie ist Adrenalin das wichtigste Medikament. Es ist daher ein herausragender Bestandteil des Notfallsets, welches Patienten nach einer anaphylaktischen Reaktion erhalten. Ein sicherer Umgang mit dem Notfallset ist essenziell und muss im Rahmen von wiederholten Schulungen geübt werden.
APA, Harvard, Vancouver, ISO, and other styles
3

Walther, Andreas. "Anaphylaxie." Intensivmedizin up2date 4, no. 03 (August 2008): 245–60. http://dx.doi.org/10.1055/s-2007-995663.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Paulun, A., T. Hoppen, T. Nüßlein, and J. Büttner. "Anaphylaxie." Monatsschrift Kinderheilkunde 165, no. 1 (November 9, 2016): 65–72. http://dx.doi.org/10.1007/s00112-016-0200-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Przybilla, B., J. Ring, and F. Ruëff. "Anaphylaxie." Der Hautarzt 58, no. 12 (November 14, 2007): 1025–31. http://dx.doi.org/10.1007/s00105-007-1434-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Merk, H. F. "Anaphylaxie." Der Hautarzt 58, no. 12 (November 18, 2007): 1023–24. http://dx.doi.org/10.1007/s00105-007-1446-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Merk, H. F., M. Worm, and K. Brockow. "Anaphylaxie." Der Hautarzt 64, no. 2 (February 2013): 80. http://dx.doi.org/10.1007/s00105-012-2454-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rietschel, E. "Anaphylaxie." DMW - Deutsche Medizinische Wochenschrift 133, S 03 (July 2008): S67—S72. http://dx.doi.org/10.1055/s-2008-1067323.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Blumenstiel, Jonas, and Andreas Bohn. "Anaphylaxie." Notfallmedizin up2date 9, no. 04 (December 2014): 339–54. http://dx.doi.org/10.1055/s-0033-1358069.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bohn, Andreas, and Jonas Blumenstiel. "Anaphylaxie." retten! 7, no. 05 (November 2018): 344–54. http://dx.doi.org/10.1055/a-0629-0619.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Anaphylaxie"

1

Gillis, Caitlin. "Neutrophils in IgG- and endotoxin-induced systemic inflammation : protective or pathological agents ?" Thesis, Paris 6, 2016. http://www.theses.fr/2016PA066279/document.

Full text
Abstract:
Les neutrophiles contribuent à l'inflammation protectrice et pathologique. Ce projet de thèse consiste à déterminer le rôle des neutrophiles dans des modèles d'inflammation systémique graves et potentiellement mortelles, induite par le lipopolysaccharide (LPS, endotoxémie) ou par des complexes immuns antigène-anticorps (anaphylaxie). L'anaphylaxie est une réaction allergique qui peut être IgE- et/ou IgG-dépendante. L’endotoxémie est un modèle pertinent de l'inflammation au cours de maladies graves. Pour étudier les neutrophiles in vivo, nous avons utilisé un nouveau modèle murin de neutropénie inductible. Nous montrons que les neutrophiles et la Myélopéroxidase qu’ils produisent ont un rôle protecteur dans le choc endotoxique, indépendamment de l'environnement microbiologique. A l'inverse, les neutrophiles peuvent contribuer à l'anaphylaxie induite par les IgG chez la souris. Comme les récepteurs pour les IgG (FcγR) murins sont très différents des humains, nous avons développé un modèle de souris knock-in dans lequel les FcγR murins a été remplacé par les FcγR humains, activateurs et inhibiteur. Chez ces souris, nous montrons que des IgG humaines peuvent induire une anaphylaxie: le FcγRIIA a un rôle dominant, via l'activation des neutrophiles, et les médiateurs PAF et histamine. En parallèle, nous développons un modèle murin d’anaphylaxie à un curare, le Rocuronium, utilisé en clinique. Au même temps, dans une étude clinique, les résultats d’analyses des échantillons sanguins des patients suspectés d’avoir subi une anaphylaxie au curare soutien notre hypothèse de travail: que l’activation des neutrophiles par des IgG spécifiques est impliquée dans l'anaphylaxie humaine
Neutrophils are agents of protective and pathological inflammation. This thesis work aimed to determine the role of neutrophils during severe, potentially fatal models of systemic inflammation induced by lipopolysaccharide (LPS, endotoxemia) or by IgG immune complexes (anaphylaxis). Anaphylaxis is a severe allergic reaction that may proceed via IgE- or IgG-dependant pathways. Endotoxemia is a model relevant to inflammation during critical illness. To study neutrophils in vivo, we employed a new mouse model of inducible neutropenia. We found, surprisingly, that neutrophils and neutrophil-derived MPO protect against the severity of endotoxic shock, independently of the microbiological environment, suggesting that neutrophils limit inflammation during endotoxemia. Conversely, neutrophils can contribute to IgG-induced anaphylaxis in mice. As mice and human IgG receptors (FcγR) are very different, we developed a novel mouse strain in which targeted insertion of human FcγR into the murine loci recapitulated hFcγR expression. Herein, using these mice, this work demonstrates that anaphylaxis induced by hIgG proceeds within a native context of activating and inhibitory hFcγRs, and that neutrophil activation via FcγRIIA is a dominant pathological pathway, involving the mediators PAF and histamine. Finally, we describe ongoing development of a mouse model of anaphylaxis in response to Rocuronium, a curare-based neuromuscular blocking agent (NMBA). In addition, as part of a collaborative clinical study we analysed blood samples from patients suspected of NMBA-induced anaphylaxis, finding evidence for the activation of a neutrophil- and IgG-dependent axis during human anaphylaxis
APA, Harvard, Vancouver, ISO, and other styles
2

Bellou, Abdelouahab. "L' anaphylaxie : approche clinique descriptive et approche expérimentale chez le rat Brown Norway sensibilisé à l'ovalbumine." Nancy 1, 2001. http://www.theses.fr/2001NAN11303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Paßmann, Benedikt [Verfasser]. "Validierung des Anaphylaxie-Registers / Benedikt Paßmann." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2015. http://d-nb.info/1075493358/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gallimidi, Emmanuel Mertes Paul Michel. "Dosage de la tryptase totale chez des patients en état de défaillance cardiocirculatoire : anaphylaxie versus non-anaphylaxie." [S.l.] : [s.n.], 2006. http://www.scd.uhp-nancy.fr/docnum/SCDMED_T_2006_GALLIMIDI_EMMANUEL.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Eckermann, Oliver [Verfasser]. "Notfalldiagnostik und Akutversorgung der Anaphylaxie / Oliver Eckermann." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2018. http://d-nb.info/1170814018/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Nassiri, Maria. "Herz-Kreislauf-Medikamente als Kofaktoren der Anaphylaxie." Doctoral thesis, Humboldt-Universität zu Berlin, Lebenswissenschaftliche Fakultät, 2015. http://dx.doi.org/10.18452/17188.

Full text
Abstract:
Die Anaphylaxie, eine potentiell lebensbedrohliche Reaktion, kann durch Kofaktoren beeinflusst werden. ACE-Inhibitoren, ß-Blocker und Acetylsalicylsäure (ASS) werden häufig in der Therapie von Herz-Kreislauferkrankungen eingesetzt. In der vorliegenden Arbeit wurde überprüft, ob diese anaphylaktische Reaktionen begünstigen. Das Modell der passiv systemischen Anaphylaxie (PSA) wurde speziell angepasst, um die Behandlung einer Herz-Kreislauf-Therapie nachzubilden. Die orale Gabe von Metoprolol oder Ramipril verstärkte die Anaphylaxie geringfügig. Die Kombination der Medikamente steigerte die Anaphylaxie deutlich, was im Modell der passiv kutanen Anaphylaxie (PCA) bestätigt werden konnte. Gleichzeitig waren Mastzellmediatoren im Serum der Tiere erhöht. Die Inkubation muriner Mastzellen (MZ) mit den Medikamenten, steigerte die FcεRI-vermittelten Histaminfreisetzung in vitro. ASS-Vorbehandlung der Mäuse verstärkte die Ausprägung der PSA und der PCA, was mit einer Steigerung von MZ-Mediatoren im Serum assoziiert war. Die FcεRI-induzierte Histaminfreisetzung muriner MZ wurde hingegen nach ASS-Inkubation gehemmt, was auf einen indirekten Mechanismus hinweist. Die Reduktion der Prostaglandine (PG) durch ASS ist mit einer gesteigerten Leukotriensynthese verbunden. Der Leukotrienantagonist Montelukast konnte die, durch ASS verstärkte, PSA nicht mildern, was zeigt, dass dieser Effekt unabhängig von Leukotrienen ist. PGE2 kann die MZ-Degranulation über EP1-EP4-Rezeptoren modulieren. Tatsächlich schwächten EP3- und EP4-Rezeptoragonisten die durch ASS gesteigerte Anaphylaxie ab. PGE2 nimmt somit eine wichtige Rolle in der pro-anaphylaktischen Wirkung von ASS ein. Zusammenfassend wurde erstmals gezeigt, dass Metoprolol und Ramipril die Anaphylaxie über eine Steigerung der MZ-Reaktivität verstärken. ASS hingegen erhöht anaphylaktische Reaktionen über einen indirekt steigernden Effekt auf die MZ. PGE2 ist zumindest teilweise an der pro-anaphylaktischen Wirkung von ASS beteiligt.
Cofactors contribute to the severity of anaphylaxis, a potential life-threatening hypersensitivity reaction. ACE-inhibitors, ß-blockers and acetylsalicylic acid (asa) are frequently used drugs in cardiovascular therapy. Whether they affect systemic anaphylactic reactions has been addressed within this thesis. To this aim, the passive systemic anaphylaxis model (PSA) was employed here and specially designed to mimic a long term treatment in cardiovascular therapy. The data demonstrate that oral treatment of mice with ramipril or metoprolol alone slightly aggravated anaphylaxis. However, the combination clearly potentiated anaphylactic reactions, which was also confirmed in the passive cutaneous anaphylaxis model (PCA). In line with this, elevated amounts of mast cell (MC) mediators were detected in mice sera upon combined drug treatment. In vitro, FcεRI-mediated histamine release of murine MCs was likewise enhanced by the respective drugs. Pre-treatment of mice with asa aggravated the symptoms of PSA and PCA; simultaneously MC-mediators in sera were elevated. In contrast, FcεRI-mediated histamine release of MCs was reduced by asa in vitro, pointing to an indirect mechanism. Asa reduces prostaglandins (PGs) and increases leukotriene synthesis. The leukotriene antagonist montelukast failed to attenuate PSA, aggravated by asa, suggesting that the pro-anaphylactic effect of asa might be independent of leukotrienes. PGE2 can modulate MC degranulation via EP1-EP4 receptor. Indeed, EP3 and EP4 receptor agonists alleviated anaphylaxis enhanced by asa. Therefore PGE2 might play an important role in the pro-anaphylactic effect of asa. In conclusion, the data demonstrate for the first time that metoprolol and ramipril exacerbate anaphylactic symptoms by a direct increase in MC reactivity. In contrast, asa aggravates anaphylactic reactions by priming MCs through an indirect mechanism. PGE2 is at least partly involved in this process.
APA, Harvard, Vancouver, ISO, and other styles
7

Moritel, Marc. "L'anaphylaxie aux corticoïdes : à propos de 4 cas et revue de la littérature." Saint-Etienne, 1991. http://www.theses.fr/1991STET6226.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rohrer, Christoph Ludwig. "Anaphylaxie: Klinik, Aetiologie und Verlauf bei 118 Patienten /." [S.l.] : [s.n.], 1999. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Balbino, Bianca. "Characterizing the role of IgG antibodies in anaphylaxis." Thesis, Sorbonne université, 2019. http://www.theses.fr/2019SORUS024.

Full text
Abstract:
L'anaphylaxie est la manifestation clinique la plus sévère de l’allergie. Il est couramment admis que chez l’homme, l’anaphylaxie est médiée par les anticorps de type IgE. Cependant, des données chez la souris indiquent que les IgG peuvent également contribuer à l’anaphylaxie. Le but de ma thèse a été de mieux comprendre comment les IgG induisent l’anaphylaxie. Dans un premier temps, nous avons démontré que les IgG murines induisent l’anaphylaxie en activant le récepteur FcγRIII à la surface des macrophages, ce qui aboutit à la libération de PAF. Nous avons ensuite voulu savoir si les IgG humaines peuvent également induire des chocs anaphylactiques. L’anticorps thérapeutique Omalizumab (IgG1 humanisée anti-IgE) induit des chocs anaphylactiques chez certains patients. Nous avons démontré que Omalizumab forme des complexes immuns qui peuvent activer les récepteurs FcγRs et induire des chocs anaphylactiques dans des souris exprimants les FcγRs humains (hFcγRKI). Nous avons ensuite développé une version mutante d’Omalizumab incapable de lier les FcγRs et démontré que cet anticorps bloque les IgE sans induire d’anaphylaxie. Finalement, nous avons développé un nouveau modèle humanisé d’anaphylaxie aux arachides dans lequel les souris hFcγRKI sont sensibilisées avec des IgG de patients allergiques aux arachiques. Nos données préliminaires indiquent que les IgG peuvent induire l’anaphylaxie dans ce modèle. De manière surprenante, l’anaphylaxie est augmentée dans des souris n’exprimant aucun FcγR. Nous étudions actuellement le(s) mécanisme(s) responsables de cet effet, et notamment l’implication de la voie du complément et le rôle du récepteur inhibiteur FcγRIIB
Anaphylaxis is a severe and potentially fatal allergic reaction. The current paradigm in humans states that anaphylaxis is triggered by allergen-specific IgE antibodies (Abs). Several reports in mice indicate that IgG Abs can also trigger anaphylaxis. The goal of my thesis was to better understand the pathways through which IgG mediate anaphylaxis. We first evaluated this in an adjuvant-free mouse model of active systemic anaphylaxis. We observed a contribution of the 'classical’ pathway mediated by IgE, FcγRI, mast cells and histamine. However, anaphylaxis was largely mediated by an ‘alternative’ pathway driven by IgG, FcγRIII, macrophages and PAF. We then examined whether human IgG can also trigger anaphylaxis. Omalizumab, an IgG1 anti-IgE mAb, has been reported to induce adverse events, including anaphylaxis. We found that Omalizumab forms immune complexes with IgE that engage FcγRs and induce both skin inflammation and anaphylaxis when injected into mice expressing all human FcγRs (hFcγRKI). We then developed an Fc-engineered version of Omalizumab which cannot bind FcγRs, and demonstrated that this Ab is as potent as Omalizumab at blocking IgE-mediated allergic reactions, but does not induce FcγR-mediated anaphylaxis. Finally, I describe ongoing work in a new model of peanut anaphylaxis in which hFcγRKI mice are sensitized with IgG from allergic subjects. Preliminary data indicate that these IgG induce anaphylaxis in this model; Surprisingly, anaphylaxis is increased in mice deficient for all FcγRs. We are now investigating the mechanism(s), in particular the implication of the complement pathway, and the role of the inhibitory receptor FcγRIIB
APA, Harvard, Vancouver, ISO, and other styles
10

Gros, Thierry. "Les accidents anaphylactoi͏̈des per opératoires : analyse de 374 bilans réalisés dans le cadre de la consultation d'allergo-anesthésie du C.H.U. Montpellier (1991-1994)." Montpellier 1, 1995. http://www.theses.fr/1995MON11160.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Anaphylaxie"

1

Canada. Ministre des apprivisionnements et services. L 'anaphylaxie: Guide à l'intention des commissions et conseils scolaires. [s.l.]: Ministre des approvisionnements et services Canada, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Canada, Canada Santé, and Association canadienne des commissions/conseils scolaires., eds. L' anaphylaxie: Guide à l'intention des commissions et conseils scolaires. Ottawa, Ont: Santé Canada, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Claude, Reyraud, ed. L'allergie, maladie de notre temps?: Asthme, hypersensibilité, acarien, pollen, anaphylaxie. [Paris]: Phare international, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bock, Gregory, and Jamie Goode, eds. Anaphylaxis. Chichester, UK: John Wiley & Sons, Ltd, 2004. http://dx.doi.org/10.1002/0470861193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ellis, Anne K., ed. Anaphylaxis. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-43205-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gregory, Bock, Goode Jamie, and Novartis Foundation, eds. Anaphylaxis. Chichester: John Wiley & Sons, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

F, Kemp Stephen, ed. Anaphylaxis. Philadelphia: Saunders, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

(Firm), S. Karger, ed. Anaphylaxis. Basel: Karger, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cingi, Cemal, and Nuray Bayar Muluk. Quick Guide to Anaphylaxis. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-33639-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Castells, Mariana C., ed. Anaphylaxis and Hypersensitivity Reactions. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60327-951-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Anaphylaxie"

1

Fischer, J., and T. Biedermann. "Anaphylaxie." In Allergologie, 223–30. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-642-37203-2_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rietschel, E., I. Huttegger, L. Lange, and R. Urbanek. "Anaphylaxie." In Weiterbildung Intensivmedizin und Notfallmedizin, 127–37. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-40738-3_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lange, L. "Anaphylaxie." In Kinderallergologie in Klinik und Praxis, 251–67. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-44632-4_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lange, Lars, Matthias V. Kopp, and Hagen Ott. "Anaphylaxie." In Kinderallergologie in Klinik und Praxis, 321–40. Berlin, Heidelberg: Springer Berlin Heidelberg, 2023. http://dx.doi.org/10.1007/978-3-662-62714-3_13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Przybilla, Bernhard, and Franziska Ruëff. "Lebensbedrohende Anaphylaxie." In Fortschritte der praktischen Dermatologie und Venerologie, 380–84. Berlin, Heidelberg: Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-30515-6_61.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hatz, R. A., W. A. Walker, and H. J. Krämling. "Gastrale Anaphylaxie." In Ökosystem Darm, 250–54. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-75075-5_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Müller-Werdan, Ursula, and K. Werdan. "Anaphylaxie und Allergie." In Kompendium der praktischen Medizin, 1437–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-59754-1_122.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wilhelm, Wolfram, and Fabian Grundmann. "Allergie und Anaphylaxie." In Praxis der Anästhesiologie, 591–600. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-54568-3_34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Wirtz, S. "Anaphylaxie, Verätzungen, Verbrennungen." In Management des schwierigen Atemwegs, 214–23. Berlin, Heidelberg: Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18701-8_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kleinhans, Dieter. "Anstrengungsinduzierte Urtikaria und Anaphylaxie." In Fortschritte der praktischen Dermatologie und Venerologie, 75–77. Berlin, Heidelberg: Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-71732-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Anaphylaxie"

1

Lakner, T., M. Cuevas, and M. Frank. "Notfallbehandlung von Anaphylaxie." In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1711482.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Drews, A., and C. Habelt. "Anaphylaxie durch Nahrungsmittel führt zu Hilflosigkeit bei einem 12-Jährigen (Merkzeichen H der VersMedV)." In 60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1678037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tolksdorf, SJ, H. Smith, M. Wagenmann, and A. Loerbroks. "Determinanten des Wissens um und Einstellungen zu Nahrungsmittelallergien und Anaphylaxie bei Gastronomie-Mitarbeiter*innen." In „Neue Ideen für mehr Gesundheit“. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1694348.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lakner, T., M. Cuevas, and M. Frank. "Emergency treatment of anaphylaxis." In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1710837.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Levent, Ayşenur, Cansu Altuntaş, Yelda Türkmenoğlu, Birol Öztürk, and Adem Karbuz. "246 Allergy or Anaphylaxis?" In 10th Europaediatrics Congress, Zagreb, Croatia, 7–9 October 2021. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2021. http://dx.doi.org/10.1136/archdischild-2021-europaediatrics.246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Starkel, S., S. Wilson, R. Plambeck, R. Mertens, and M. Malesker. "Anaphylaxis Following Rocuronium Administration." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2629.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Abdelghany, Y., J. Resnyk, A. Nadi Khalil, A. Zimrin, and J. J. Rose. "A Case of Anaphylaxis Associated Thrombocytopenia." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Schwartz, David G., Abdelouahab Bellou, Luis Garcia-Castrillo, Antonella Muraro, and Nikolaos G. Papadopoulos. "Towards chronic emergency response communities for anaphylaxis." In 2014 IEEE International Conference on Information Reuse and Integration (IRI). IEEE, 2014. http://dx.doi.org/10.1109/iri.2014.7051878.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bilal, M. I., B. Prayson, A. Nasrullah, M. Simpson, and S. Sangli. "A Rare Case of Dalbavancin Induced Anaphylaxis." In American Thoracic Society 2023 International Conference, May 19-24, 2023 - Washington, DC. American Thoracic Society, 2023. http://dx.doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a3066.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hota, Gopabandhu, Abhilash Nandy, Kshitiz Goel, Dishank Yadav, Saumo Pal, and Ankush Roy. "An Adaptive Anaphylaxis Detection and Emergency Response System." In 2019 IEEE 32nd International Symposium on Computer-Based Medical Systems (CBMS). IEEE, 2019. http://dx.doi.org/10.1109/cbms.2019.00019.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Anaphylaxie"

1

Turner, Paul, Alessia Baseggio Conrado, and Jennifer Quint. Using NHS Data to Monitor Trends in the Occurrence of Severe, Food-Induced Allergic Reactions Work Package 1. Food Standards Agency, August 2024. http://dx.doi.org/10.46756/sci.fsa.lvn457.

Full text
Abstract:
People with food allergies may experience food allergic reactions due to accidental exposure. These reactions are commonly categorised as non-severe, fatal food anaphylaxis and near-fatal food anaphylaxis. Non-severe allergic reactions to food are more common with an incidence of up to 1,000 times greater than fatal food-related anaphylaxis. However, obtaining accurate data relating to the circumstances under which these reactions occurred is challenging under the current diagnosis coding system used in the National Health Service (NHS). This project addressed two key questions: What are the trends in the occurrence of food hypersensitivity (FHS) reactions and their consequences in terms of healthcare encounters (both to hospital and primary care)? What are the circumstances surrounding severe, life-threatening reactions to food? Approach The researchers used existing NHS datasets (relating to Hospital Admissions, Accident & Emergency visits, Critical Care admissions and Primary care visits) to evaluate healthcare encounters due to food hypersensitivity over the study period. Patient pathways through the healthcare system were also assessed by linking these different datasets. Key Results Food-induced anaphylaxis represented 29.4% of reported anaphylaxis. admissions, and increased significantly from 1.23 to 4.02 admissions per 100,000 population per annum over the study period. However, despite an annual increase of 5.7% in hospitalisation for food-induced anaphylaxis between 1998 and 2018, the case fatality rate (proportion of hospital admissions associated with a fatal outcome) more than halved, from 0.7% in 1998 to less than 0.3% in 2018. 152 deaths were identified during the study period where the cause was very likely to have been food-induced anaphylaxis. At least 86 (46%) fatalities were triggered by peanut or tree nuts. Cows’ milk was reported to be the most common cause of fatal anaphylaxis in children aged under 16 years. Using data from England for the period 2008-2018, the prevalence of food allergy ranged from 4% in preschool-aged children (under 5 years), 1-2% in school-aged children and young people (5 to <20 years) and 0.9% in adults. Although the same methods were used throughout the study period, the statistics presented may be prone to limitations such as miscoding and incomplete datasets. Prescription of adrenaline auto-injector devices (AAI) are an important risk management intervention in people at risk of food-induced anaphylaxis. However, there is significant under-prescribing of AAI. Data showed that 40% of individuals with prior food-induced anaphylaxis were not prescribed AAI and at least 59% did not have AAI on repeat prescription. Most healthcare visits for food allergy occurred in general practice. Less than 3% of individuals with a diagnosis of food allergy attended Accident and Emergency during the study period, 2008-2018. Therefore, using hospital data in isolation to analyse patterns of health service utilisation with respect to FHS may not provide a comprehensive overview.
APA, Harvard, Vancouver, ISO, and other styles
2

Turner, Paul. Using NHS Data to Monitor Trends in the Occurrence of Severe, Food-Induced Allergic Reactions Work Package 2. Food Standards Agency, August 2024. http://dx.doi.org/10.46756/sci.fsa.vji996.

Full text
Abstract:
People with food allergies may experience food allergic reactions due to accidental exposure. These reactions are commonly categorised as non-severe, fatal food anaphylaxis and near-fatal food anaphylaxis. Non-severe allergic reactions to food are more common with an incidence of up to 1,000 times greater than fatal food-related anaphylaxis. However, obtaining accurate data relating to the circumstances under which these reactions occurred is challenging under the current diagnosis coding system used in the National Health Service (NHS). This project addressed two key questions: What are the trends in the occurrence of food hypersensitivity (FHS) reactions and their consequences in terms of healthcare encounters (both to hospital and primary care)? What are the circumstances surrounding severe, life-threatening reactions to food? Approach A UK arm of NORA was established using the same online platform as the existing European Registry. Participation of healthcare professionals and/or patients to enter relevant information was co-ordinated by BSACI in conjunction with the Paediatric Emergency Research in the United Kingdom & Ireland (PERUKI) network. Different versions of the questionnaire were developed to increase response rates: (1) a comprehensive form mapped to existing NORA data fields for completion by Healthcare Professionals in the non-acute setting; (2) a shorter form with key data fields to increase data reporting in more pressured, acute healthcare settings; and (3) a form for completion by patients or their parent/guardian. Key Results The launch of the UK anaphylaxis registry faced delays and was impacted by significant pressures on NHS services due to the COVID-19 pandemic. This led to a lower than anticipated uptake of the Registry by clinics and Accident & Emergency departments. As a result, only a minority of accidental reactions (less than 5%) were captured in the registry, almost all in children and young people under age 18 years. Some indicative results of this analysis are the following: 213 cases reported to be due to a food trigger and of these, 208 occurred in children/young people aged 18 years or under. Common food triggers were peanut, tree nuts (especially cashew), cow’s milk/dairy and hen’s egg. 47% of reactions occurred after consumption of prepacked food products and in at least 59% of these cases, the allergen was declared as an actual ingredient. Further work would be needed to understand how to optimise reporting of data, for example by reducing the time burden for completion by clinicians and patients.
APA, Harvard, Vancouver, ISO, and other styles
3

Pühringer, Vanessa, Bernd Jilma, and Harald Herkner. Population-based incidence of all-cause anaphylaxis and its development over time: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2023. http://dx.doi.org/10.37766/inplasy2023.3.0047.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gidengil, Courtney, Matthew Bidwell Goetz, Margaret Maglione, Sydne J. Newberry, Peggy Chen, Kelsey O’Hollaren, Nabeel Qureshi, et al. Safety of Vaccines Used for Routine Immunization in the United States: An Update. Agency for Healthcare Research and Quality (AHRQ), May 2021. http://dx.doi.org/10.23970/ahrqepccer244.

Full text
Abstract:
Objective. To conduct a systematic review of the literature on the safety of vaccines recommended for routine immunization in the United States, updating the 2014 Agency for Healthcare Research and Quality (AHRQ) report on the topic. Data sources. We searched MEDLINE®, Embase®, CINAHL®, Cochrane CENTRAL, Web of Science, and Scopus through November 9, 2020, building on the prior 2014 report; reviewed existing reviews, trial registries, and supplemental material submitted to AHRQ; and consulted with experts. Review methods. This report addressed three Key Questions (KQs) on the safety of vaccines currently in use in the United States and included in the Centers for Disease Control and Prevention’s (CDC) recommended immunization schedules for adults (KQ1), children and adolescents (KQ2), and pregnant women (KQ3). The systematic review was supported by a Technical Expert Panel that identified key adverse events of particular concern. Two reviewers independently screened publications; data were extracted by an experienced subject matter expert. Studies of vaccines that used a comparator and reported the presence or absence of adverse events were eligible. We documented observed rates and assessed the relative risks for key adverse events. We assessed the strength of evidence (SoE) across the existing findings from the prior 2014 report and the new evidence from this update. The systematic review is registered in PROSPERO (CRD42020180089). Results. A large body of evidence is available to evaluate adverse events following vaccination. Of 56,608 reviewed citations, 189 studies met inclusion criteria for this update, adding to data in the prior 2014 report, for a total of 338 included studies reported in 518 publications. Regarding vaccines recommended for adults (KQ1), we found either no new evidence of increased risk for key adverse events with varied SoE or insufficient evidence in this update, including for newer vaccines such as recombinant influenza vaccine, adjuvanted inactivated influenza vaccine, and recombinant adjuvanted zoster vaccine. The prior 2014 report noted a signal for anaphylaxis for hepatitis B vaccines in adults with yeast allergy and for tetanus, diphtheria, and acellular pertussis vaccines. Regarding vaccines recommended for children and adolescents (KQ2), we found either no new evidence of increased risk for key adverse events with varied SoE or insufficient evidence, including for newer vaccines such as 9-valent human papillomavirus vaccine and meningococcal B vaccine. The prior 2014 report noted signals for rare adverse events—such as anaphylaxis, idiopathic thrombocytopenic purpura, and febrile seizures—with some childhood vaccines. Regarding vaccines recommended for pregnant women (KQ3), we found no evidence of increased risk for key adverse events with varied SoE among either pregnant women or their infants following administration of tetanus, diphtheria, and acellular pertussis vaccines during pregnancy. Conclusion. Across this large body of research, we found no new evidence of increased risk since the prior 2014 report for key adverse events following administration of vaccines that are routinely recommended. Signals from the prior report remain unchanged for rare adverse events, which include anaphylaxis in adults and children, and febrile seizures and idiopathic thrombocytopenic purpura in children. There is no evidence of increased risk of adverse events for vaccines currently recommended in pregnant women. There remains insufficient evidence to draw conclusions about some rare potential adverse events.
APA, Harvard, Vancouver, ISO, and other styles
5

Grundy, Helen H., Lucy C. Brown, Mark Sykes, M. Rosario Romero, and Dominic Anderson. Review of allergen analytical testing methodologies. Food Standards Agency, September 2023. http://dx.doi.org/10.46756/sci.fsa.noe660.

Full text
Abstract:
The Food Information Regulation (FIR) states that accurate and understandable allergen information needs to be supplied to consumers for the 14 priority allergens. Food allergies affects between 1-2% of the UK population, with some allergens responsible for hospital admissions with anaphylaxis. Food businesses have a legal responsibility to provide food that is safe, which means declaring allergens present as ingredients and warning consumers about their potential unintended presence due to cross-contact. A system needs to be implemented for testing allergens in foods, responding to incidents, and manage risks to protect consumers. This review was prepared to inform FSA on the current state of the art of allergen testing methodologies and the remaining challenges. This project combined a critical literature review of testing methods with assessments of allergen proficiency testing data, consultation with stakeholders from the food industry, and consultation with industry experts regarding multiplex methodologies and the harmonisation of methods in an unbiased review of the current status of testing capabilities for the 14 EU-retained regulated food allergens. Gaps in testing capabilities were highlighted in order to inform future direction, including a lack of transparent public data for the performance and applicability of commercial test kits. Cross-reactivities of kits were also highlighted along with the need for development of fast and accurate point-of-use tests to support food production. A review of allergen proficiency testing data revealed gaps in testing capabilities and variations between the outputs of different test kits when testing for the same allergen. This review critically compares current testing methods to progress towards a suitable harmonised testing protocol that facilitates allergen risk management, and to mitigate limitations and evidence gaps. Suitable workflows outlining recommended testing protocols are presented for priority allergens to provide a resource for compliant testing and incident management. Estimations of the cost of setting up new testing laboratories to support allergen workflows are also included in addition to detailing the cost of testing by established laboratories.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Anaphylaxie' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography